Brand Name | Status | Last Update |
---|---|---|
cafcit | New Drug Application | 2024-04-08 |
caffeine citrate | ANDA | 2025-07-28 |
caffeine citrate oral solution | ANDA | 2023-07-31 |
excedrin pm triple action caplets and excedrin extra strength pain reliever | C200263 | 2024-03-14 |
excedrin pm triple action caplets and excedrin tension headache | C200263 | 2024-03-14 |
fioricet | ANDA | 2021-01-01 |
fioricet with codeine | ANDA | 2021-03-01 |
norgesic | ANDA | 2024-01-08 |
norgesic forte | ANDA | 2024-01-27 |
orphenadrine citrate aspirin caffeine | ANDA | 2024-07-25 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 1 | — | — | 1 |
Drug common name | Caffeine citrate |
INN | — |
Description | Caffeine citrate, sold under the brand name Cafcit among others, is a medication used to treat a lack of breathing in premature babies. Specifically it is given to babies who are born at less than 35 weeks or weigh less than 2 kilograms (4.4Â lb) once other causes are ruled out. It is given by mouth or slow injection into a vein.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O |
PDB | — |
CAS-ID | 2097117-68-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1200569 |
ChEBI ID | — |
PubChem CID | 6241 |
DrugBank | — |
UNII ID | — |